0B68 Glass, Jon - Thomas Jefferson University - Thomas Jefferson University
jxg168

Jon Glass, MD

Contact Dr. Glass

909 Walnut Street
Philadelphia, PA 19107

(215) 503-7005
(215) 503-9357 fax

Most Recent Peer-reviewed Publications

  1. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to l-dopa in the treatment of Parkinson's disease: A randomized, multicenter, open-label, parallel-group study
  2. Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease
  3. The Parkinson-control study: A 1-year randomize, double-blind trial comapring piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease
  4. High Dose Treatment of Parkinson's Disease with α-Dihydroergocryptine | Hochdosistherapie des Morbus Parkinson mit α-Dihydroergocryptin
  5. Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen
  6. Workshop III: Late motor complications of Parkinson's disease
  7. Better efficacy of lisuride by using higher doses | Bessere wirksamkeit von lisurid durch verwendung hoherer dosen
  8. High-dose gadolinium-enhanced MRI for diagnosis of meningeal metastases
  9. Gliomatosis cerebri presenting with optic nerve involvement: MRI
  10. MRI in hemiballismus due to subthalamic nucleus hemorrhage: An unusual complication of liver transplantation
  11. Pure motor hemiplegia including the face induced by an infarct of the medullary pyramid
  12. Hemiballismus: CT and MR findings
  13. Cerebrovascular complications in cancer patients: Commentary II
  14. The diagnosis and treatment of stroke in a patient with cancer: Nonbacterial thrombotic endocarditis (NBTE): A case report and review
  15. The etiology of idiopathic Parkinson's disease. An epidemiologic perspective with implications for preventive measures | DIE ATIOLOGIE DES MORBUS PARKINSON. EINE EPIDEMIOLOGISCHE PERSPEKTIVE MIT MOGLICHEN IMPLIKATIONEN FUR DIE PRAVENTION
  16. Uncovering ocular pseudomyasthenia.
  17. Leptomeningeal metastasis [1]
  18. Neurotoxicity of interferon-alpha [1]
  19. Current progress in the treatment of Parkinson's disease
  20. Neurological manifestations in neurosarcoidosis: Investigations in patients with pulmonary sarcoidosis | NEUROLOGISCHE SYMPTOMATIK UND DEREN TOPISCHE ZUORDNUNG BEI DER NEUROSARKOIDOSE: UNTERSUCHUNGEN AN PATIENTEN MIT PULMONALER SARKOI 011D DOSE
0